Swissmedic has announced a precautionary recall of specific batches of Locametz 25 mcg Multidose Kits for radiopharmaceutical applications. Clinical teams, hospital pharmacies, and regulatory staff should take note of this important development to ensure patient safety and regulatory compliance.
What changed?
On January 10, 2026, Swissmedic released a statement reporting the recall of Locametz 25 mcg Multidose Kits for a radiopharmaceutical purpose. The affected batches include PG21CH2507 and PG21CH2508, with Bulk Batch ID F0392504. The recall reaches as far as the retail level, including clinics and hospitals.
Locametz is a critical product used in radiopharmaceutical preparation, making adherence to stringent quality and safety standards crucial. Concerns specific to these batches have prompted this proactive regulatory action.
Who is affected?
The recall significantly impacts clinical institutions and healthcare facilities that utilise Locametz for radiopharmaceutical purposes. Hospital pharmacies and nuclear medicine departments are urged to check their inventories urgently. Additionally, distributors and intermediaries supplying these batches need to halt product distribution immediately.
Official batch details
The recall applies explicitly to:
- Locametz 25 mcg Multidose Kits
- Batch numbers: PG21CH2507 and PG21CH2508
- Bulk Batch ID: F0392504
Healthcare institutions are advised to isolate these specific items to prevent their accidental use pending further instructions.
FAQ
1. Why were these batches recalled?
The recall was initiated as a precautionary measure based on findings suggesting quality concerns that could impact the product’s safety or efficacy. More specific details were not disclosed publicly.
2. What should I do with affected inventory?
Immediately segregate any affected batches from your inventory and ensure they are not used. Contact relevant distributors or Swissmedic if further instruction is required.
3. Where can I find more information?
For comprehensive details, refer to the official Swissmedic announcement provided in the link below.
Actions needed
Healthcare providers and stakeholders involved in handling Locametz products are advised to:
- Immediately check inventory for affected batch numbers.
- Isolate and label affected products.
- Contact the relevant distributor or follow Swissmedic instructions for further steps.
Ensuring patient safety remains the topmost priority during this process.
Disclaimer
This article is intended for informational purposes only and does not serve as legal or professional advice. Healthcare professionals are encouraged to consult official regulatory communications and professional guidance for further clarity.
Swissmedic announcement
For full information about the Swissmedic announcement, see the link below.